Literature DB >> 24219035

Mechanisms of action of methotrexate.

Edwin S L Chan, Bruce N Cronstein.   

Abstract

As one of the most utilized disease-modifying anti-rheumatic drugs, methotrexate (MTX) has revolutionized the treatment of rheumatoid arthritis as well as many other non-rheumatic chronic inflammatory diseases. Far from a simple anti- proliferative agent as was once thought, our understanding of how it exerts its anti-inflammatory effects has grown over the years. The mechanisms of action of MTX are reviewed here, and we look at how this knowledge helps to explain some of its most common side effects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24219035

Source DB:  PubMed          Journal:  Bull Hosp Jt Dis (2013)        ISSN: 2328-4633


  39 in total

1.  Protective effects of carvacrol against methotrexate-induced testicular toxicity in rats.

Authors:  Mansur Daggulli; Onur Dede; Mehmet Mazhar Utangac; Mehmet Nuri Bodakci; Namık Kemal Hatipoglu; Necmettin Penbegul; Ahmet Ali Sancaktutar; Yaşar Bozkurt; Gül Türkçü; Hatice Yüksel
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire).

Authors:  Nibah Fatimah; Babur Salim; Amjad Nasim; Kamran Hussain; Harris Gul; Sarah Niazi
Journal:  Clin Rheumatol       Date:  2016-04-06       Impact factor: 2.980

3.  Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.

Authors:  Pedro Iván Santos-Moreno; José de la Hoz-Valle; Laura Villarreal; Analhi Palomino; Guillermo Sánchez; Carlos Castro
Journal:  Clin Rheumatol       Date:  2014-10-17       Impact factor: 2.980

Review 4.  Novel Antiatherosclerotic Therapies.

Authors:  Peter Libby; Brendan M Everett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

5.  Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate.

Authors:  Ryan S Funk; Leon van Haandel; J Steven Leeder; Mara L Becker
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

6.  Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.

Authors:  Arduino A Mangoni; Leena R Baghdadi; E Michael Shanahan; Michael D Wiese; Sara Tommasi; David Elliot; Richard J Woodman
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-08-01       Impact factor: 5.346

7.  One-Carbon Metabolism and Colorectal Cancer: Potential Mechanisms of Chemoprevention.

Authors:  Matthew P Hanley; Daniel W Rosenberg
Journal:  Curr Pharmacol Rep       Date:  2015-06

8.  The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.

Authors:  Tomas Soukup; Martin Dosedel; Petr Pavek; Jana Nekvindova; Ivan Barvik; Iva Bubancova; Petr Bradna; Ales Antonin Kubena; Alejandro Fernández Carazo; Tomas Veleta; Jiri Vlcek
Journal:  Rheumatol Int       Date:  2015-01-25       Impact factor: 2.631

Review 9.  Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?

Authors:  Sujani Yadlapati; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2016-03-02       Impact factor: 2.631

10.  Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry.

Authors:  Prashant Kaushik; Daniel H Solomon; Jeffrey D Greenberg; James T Anderson; George Reed; Ozlem Pala; Bahar Sumbul-Yuksel; Pooja Kadam; Joel M Kremer
Journal:  Clin Rheumatol       Date:  2015-08-05       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.